As every company’s progress is steered by its founders and mentors, E-Spin Nanotech endowed with an outstanding personality in the name of Dr. Sandip Patel as director of the company and renowned mentors Prof Ashutosh Sharma from IIT-Kanpur. Dr. Sandip Patil is an alumnus of IIT-Kanpur, he is a passionate researcher at the first place who is often proclaimed as an epitome of entrepreneurship at IIT-K. He holds a doctorate degree in Chemical Engineering and specializes in the field of Nanotechnology and Adhesives. His keen interest for research is well-complimented by his strong publication track record in reputed journals. He is also a co-inventor of an Indian patent on composite reusable adhesive and that of a US patent which is under process. Some of his innovative work on fabrication of composite reusable adhesives has featured in scientific news in CNN (U.S. edition), Mint and the Wall Street Journal. He is a recipient of many distinguished awards which stand as a testimony to his entrepreneurship and research abilities; it includes IIChE Shah-Schulman Award for the best PhD Thesis (2013), UICT Jalgaon alumni award for Young Entrepreneur (2013), Rajeev Motwani Young Entrepreneur award by Motwani foundation (2014) and Indian School of Business Hyderabad Scholarship (2013).
Dr. Surya has 30 years of research experience and has held leadership positions of increasing seniority in the industry. He has extensive experience in the assessment of drug molecules against several target classes across a range of therapeutic areas and specializes in building high performance research teams. His past organizations include SmithKline Beecham, Ranbaxy, and TCG Lifesciences (Chembiotek). Dr. Surya has an integrated Masters in Physics from IIT Kanpur and a Ph.D. in Biophysics from Syracuse University, (USA).
Ajit Gill (right) president and CEO. He served most recently as CEO of Nektar Therapeutics (previously Inhale Therapeutic Systems). With Gill's appointment, Auspex's founder and former CEO, Sepehr Sarshar has assumed the position of chief technology officer. "Auspex has been working for over five years to build a leadership position in the application of targeted deuteration of pharmaceuticals to meet specific clinical and market needs," says Gill. "I am very pleased to join the Auspex team. I believe the company's technology and business strategy have the potential not only to produce best-in-class drugs, but to do so while lowering time, risk and cost of drug development."
Dr. Jugnu Jain is a molecular geneticist and cell biologist by training. She obtained her PhD from Cambridge University (UK), followed by a post-doc and Instructorship at Dana Farber Cancer Institute and Harvard Medical School at Boston. Her area of research was cytokine gene regulation. After her post-doc, Dr. Jain joined Vertex Pharmaceuticals where she steered multiple drug discovery projects. She led Vertex’s global Immune-Inflammation team, and has significant experience in cancer and diabetes area as well. Prior to founding Sapien and Saarum, Jugnu was a Research Fellow & Disease Area Expert for Multiple Sclerosis helping guide research strategy, evaluating innovative technologies and forging productive scientific collaborations. Dr. Jain returned to India in 2011 to launch Sapien and Saarum along with her co-founders, Prithi and Sreevatsa. Jugnu has published over 20 papers in leading journals including Nature and Science and has two patents in her name.
Dr Kamal K Sharma is a graduate in chemical engineering from the Indian institute of Technology (IIT), Kanpur, with a post-graduate diploma in industrial management from Jamnalal Bajaj Institute of management Studies, Mumbai, and a Ph.D in economics from IIT, Mumbai. He has also completed an advanced management program from Harvard Business School, Boston.
In a career spanning more than three decades, Dr. Sharma has held a range of senior management positions managing projects, corporate development and general management in the pharmaceuticals and chemicals industries.
Earlier Computation Chemist at Vertex Pharmaceuticals in Cambridge, MA., at present he runs his own run boutique consulting operation called Nyrasta LLC., USA